joybet88 login
2025-01-09   

joybet88 login Aurora's self-driving truck tech boosts Bozeman job market

Alyssa Nakken, the first woman coach in Major League Baseball history, is leaving the Giants to join the Cleveland Guardians as an assistant in player development, as first reported by 95.7 The Game’s Steven Rissotto. Nakken is the latest member of last year’s coaching staff to depart from the team, joining Justin Viele (Rangers), Pedro Guerrero (Marlins) and Bryan Price (stepped down). Additionally, Pete Putila, the team’s general manager in 2023 and 2024, and Michael Schwartze, the team’s former director of baseball analytics, have joined the Braves. In Cleveland, Nakken will be reunited with a pair of former Giants coaches in Craig Albernaz and Kai Correa. Under Stephen Vogt, the 2024 American League Manager of the Year, Albernaz is an associate manager while Correa is a field instructor. Nakken, 34, made no shortage of history during her five seasons with the team. On April 12, 2022, Nakken became the first woman to appear in an on-field role, coaching first base after former first base coach Antoan Richardson was ejected. Last offseason, the Giants interviewed Nakken for their vacant manager opening after firing Gabe Kapler, becoming the first woman to interview for the position. The jersey that Nakken wore during her first major league game on July 23, 2020 was sent to the National Baseball Hall of Fame and Museum. Earlier this year, Nakken gave birth to her first child, Austyn. A standout softball player at Sacramento State, Nakken first joined the Giants in 2014 as a baseball operations intern, serving various front-office roles before joining the major-league coaching staff. ©2024 MediaNews Group, Inc. Visit at mercurynews.com . Distributed by Tribune Content Agency, LLC.Phillips 66 stock falls Friday, underperforms market

Pacific Northwest Sportswatch Daily Listings

Amazon director Jonathan Rubinstein sells $1 million in stock

TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, has announced significant findings from an expanded preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, consistently ranked one of the top ten hospitals in the world 1 , the study builds on previously announced preliminary results 2 on June 28, 2024 and strengthens the suggestion of a promising treatment pathway for glaucoma, the leading cause of irreversible blindness globally 3 . The Optic Nerve Disorders treatment market is expected to grow from 5.54 (USD Billion) in 2023 to 11.5 (USD Billion) by 2032, at a compound annual growth rate (CAGR) of ~8.46% during the forecast period 4 . Researchers utilized a rodent model of optic nerve crush (ONC) to simulate the damage associated with conditions like glaucoma. After inducing injury, ExoPTEN was administrated via direct injection into the eyes. The study expanded on earlier findings which indicated that eyes treated with ExoPTEN regained nearly normal retinal activity, as evidenced by electrical tests. Expanded analyses of the study data showed clear recovery of signal transmission in treated eyes compared to untreated controls, which showed no significant response. Additionally, imaging results by optical coherence tomography (OCT) scans indicates and validates that in all of treated eyes (naïve exosome treatment or ExoPTEN treatment) a successful ONC procedure has been performed (Figure 1). The study also showed that ExoPTEN treatment significantly enhanced the survival of retinal ganglion cells - key neurons responsible for transmitting visual information to the brain. Detailed analysis of retinal flat-mounts confirmed this effect, with treated eyes exhibiting substantially higher counts of these cells compared to untreated or control-treated eyes (Figures 2A and 2B). Dr. Ifat Sher, the lead investigator from the Goldschleger Eye Institute, commented, “the results from this expanded study are extremely encouraging. ExoPTEN demonstrates potential as a treatment that restores functionality and offers neuroprotection. The study shows clear signal recovery, healthier optic nerve structures and preserved retinal ganglion cells. These results suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma. Encouraged by these results, we are advancing to a larger study with more animals to validate and expand upon these findings.” Dr. Lior Shaltiel, CEO of NurExone, added, “these findings are an important step forward in our mission to develop groundbreaking therapies for regenerative medicine in several indications. ExoPTEN’s ability to repair both the structure and function of the optic nerve highlights its transformative potential for addressing vision loss and improving tens of millions of patient lives.” About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (“ TSXV ”) and OTCQB listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, minimally-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The NurExone platform technology is expected to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. For additional information and a brief interview, please watch Who is NurExone? , visit www.nurexone.com or follow NurExone on LinkedIn , X (formerly Twitter) , Facebook or YouTube Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Oak Hill Financial Inc. 2 Bloor Street, Suite 2900 Toronto, Ontario M4W 3E2 Investor Relations - Canada Phone: +1-647-479-5803 Email: info@oakhillfinancial.ca Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu Allele Capital Partners Investor Relations - US Phone: +1 978-857-5075 Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the results of the Company’s preclinical trials and its suggestion of a promising treatment pathway for glaucoma; the growth of the Optic Nerve Disorders treatment market; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN having the potential to address vision loss and improve patient lives; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including : the a bility to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company’s ability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market continuing to grow as stated; the Company expanding to further studies; the Company developing groundbreaking therapies for regenerative medicine in several indications; ExoPTEN addressing vision loss and improve patient lives; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to : the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the Company’s inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company’s inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine; the Optic Nerve Disorders treatment market decreasing and/or plateauing ; the Company ’s inability to expand into further studies; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications ; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27 , 202 4 , a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 1 https://www.afsmc.org/2024/02/sheba-medical-center-named-a-newsweek-worlds-best-hospital-for-the-6th-consecutive-year/ 2 https://www.globenewswire.com/news-release/2024/06/28/2906122/0/en/NurExone-s-ExoPTEN-Being-Studied-as-Glaucoma-Treatment-for-US-3-4-Billion-Market.html 3 https://www.mdpi.com/1424-8247/17/10/1261 4 https://www.marketresearchfuture.com/reports/optic-nerve-disorders-treatment-market-30051 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e682a60-3287-44b2-b7da-08ebed8fa807Maine approves Unitil’s $72 million acquisition of Bangor Natural Gas

‘Better Call Santa’ lets your children talk to Santa thanks to AI

Related hot word search:

Previous: 8bet casino
Next: qbet casino